Tech-Enabled Rural Health Care Leader Hopscotch Primary Care Announces $53 Million in Latest Funding Round
Hopscotch Primary Care, a technology-enabled primary care model that serves patients in rural communities, has raised $53 million in its series D financing. Founded in 2021, the company serves more than 15,000 patients across the Southeastern United States, with its largest concentration in rural Western North Carolina. Hopscotch will use the new funding to deepen access across the region, expand into new rural markets, and continue to scale its technology-powered operations. Lead investors in the round include 8VC and Town Hall Ventures, with participation from existing investors including aMoon Fund, Citi Impact Fund, Alumni Ventures and K2 HealthVentures. New investors in the round include the Autism Impact Fund (AIF), John Doerr, Chairman of Kleiner Perkins, and Dr. Richard Merkin, Founder of Heritage Provider Network, and the Leon Levine Foundation.
Mighty Therapeutics Secures Up to $150 Million to Progress Commercial and Clinical Development of New Class of Mitochondrial Targeted Medicines
Mighty Therapeutics Holdings Inc., a commercial-stage biotechnology company pioneering a new class of medicines that directly target mitochondrial dysfunction in rare and age-related diseases, today announced the closing of transactions securing up to $150 million in non-dilutive growth and equity capital. The Company has entered into an agreement with K2 HealthVentures (K2HV), an alternative investment firm that provides flexible, long-term financing solutions in life sciences and healthcare, to provide a credit facility of up to $125 million, including an initial $30 million tranche. The Company has also held an initial closing of its Series B financing, in which founding investor Morningside has invested $25 million.
Cartesian Therapeutics Secures up to $150 Million of Non-Dilutive Financing from K2 HealthVentures and Expects Topline Data from the Phase 3 AURORA Trial in First Quarter 2027
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that it has entered into an agreement with K2 HealthVentures LLC (“K2HV”), an alternative investment firm that provides flexible, long-term financing solutions in life sciences, to provide a credit facility of up to $150 million including an initial $50 million tranche. The proceeds from the initial tranche under the credit facility are expected to allow the Company to accelerate the ongoing investment in the commercial launch preparation activities for Descartes-08 in myasthenia gravis (MG) and myositis and to extend cash runway into 2028. The Company also announced progress across its pipeline, including updated timelines for all ongoing trials of Descartes-08, an autologous anti-B cell maturation antigen (BCMA) mRNA chimeric antigen receptor T-cell therapy (CAR-T).
Honest Health Raises $140 Million to Advance Value-Based Care for Health Systems
Honest Health today announced a $140 million capital raise, led by NewSpring Healthcare, a sector-focused strategy of NewSpring dedicated to partnering with innovative healthcare companies. The investment reflects growing demand for Honest Health's health system-focused approach and its track record of helping organizations execute successfully in value-based payment models.
Zarminali Pediatrics Raises $110M Series A To Transform American Pediatric Care
Zarminali Pediatrics, the first outpatient pediatric destination purpose-built to provide integrated primary and specialty care nationwide, today announced a $110M Series A funding round. Healthier Capital led the round, along with participation from existing investor General Catalyst, and new investor K2 HealthVentures.
Kandu, Inc. Announces Appointment of Marshal Linder to Board of Directors and Strategic Growth Investment from K2 HealthVentures and Piper Sandler Merchant Bank
Kandu, Inc., a healthcare technology company pioneering integrated stroke recovery solutions for post-stroke care, today announced the appointment of Marshal Linder to its Board of Directors. The company also announced the completion of a strategic growth capital investment from K2 HealthVentures and Piper Sandler Merchant Bank, with Toby AuWerter joining the Board in an observer capacity.
Apella Raises $80 Million in Series B to Transform the Hospital with Ambient AI and Computer Vision
Apella, a health technology company, today announced it raised $80 million in Series B equity and venture debt. The round was led by HighlandX, with returning investors Vensana Capital, Casdin Capital, PFM Health Sciences, Upside Partnership, and Operator Partners, and includes new investors K2 HealthVentures, OpAmp Capital, and Houston Methodist.
Phil Secures $60 Million Growth Capital Facility from K2 HealthVentures to Accelerate AI Integration
Phil, a leading software-driven pharmaceutical commercialization platform, today announced a $60 million growth debt financing from K2 HealthVentures (K2HV), a healthcare and life sciences-focused investment firm. The funding will accelerate the integration of artificial intelligence across Phil's platform and support continued customer expansion across a broad range of therapeutic areas.
Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update
Neumora today announced that it has entered into a venture debt facility for up to $125 million with K2 HealthVentures, an alternative investment firm that provides flexible, long-term financing solutions in the life sciences and healthcare industries. Under the terms of the facility, $20 million was drawn at closing, with an additional $20 million available to be drawn at Neumora’s option by December 31, 2025. The additional $85 million will be available for drawdown at Neumora's option upon the achievement of certain milestones.
Umoja Biopharma Announces Oversubscribed $100 Million Series C Financing to Advance In Vivo CAR T Pipeline through Key Oncology Clinical Milestones
Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo cell therapies that aim to realize the full reach and promise of CAR T cells, today announced the closing of a $100 million Series C financing. The financing was co-led by Double Point Ventures and DCVC Bio, with participation from new and existing investors including ARK Invest, Cormorant Asset Management, MPM Capital, Qiming Venture Partners USA, RTW Investments, Alexandria Venture Investments, SoftBank Vision Fund 2, CaaS Capital, Emerson Collective Investments managed by Yosemite, K2 HealthVentures, Myeloma Investment Fund, University of Minnesota Endowment, and other prominent life science investors.
Evergreen Nephrology Raises $130 Million to Transform and Expand Access to Value-Based Kidney Care
Evergreen Nephrology, a leader in value-based kidney care, today announced it has raised $130 million in capital to expand its care model to more patients living with kidney disease. Funding was led by Rubicon Founders, Oak HC/FT and a group of existing investors, with the addition of K2 HealthVentures. Funding will fuel Evergreen's growth by enabling its expansion into new regions while implementing advanced technologies to improve clinical outcomes, streamline care delivery, and ease the administrative burden on nephrologists.
Life Science Cares Boston launches Health Equity Portfolio Co-Investment Program as part of Anti-Poverty Strategy for Greater Boston
[Cambridge, MA June 3, 2024] — Life Science Cares Boston (LSC Boston), an anti-poverty nonprofit organization rooted in the life sciences, is proud to announce the launch of a new grantmaking program aimed at addressing health inequities among low-income families and communities in the Greater Boston area. K2 HealthVentures, an alternative investment firm that provides flexible, long-term financing solutions in the life sciences and healthcare industries, has partnered with LSC Boston as the seed funder for this initiative.
Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures
CHARLOTTESVILLE, Va., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (“AβOs”) for the treatment of Alzheimer’s disease (“AD”), today announced that it has entered into a senior secured loan and security agreement (the “Loan Agreement”) with K2 HealthVentures, a healthcare-focused specialty finance company.
MindMed Secures $50.0 Million Credit Facility with K2 HealthVentures
NEW YORK, August 14, 2023 — Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, today announced that it has entered into a senior secured credit facility with K2 HealthVentures, a healthcare-focused specialty finance company.
Coherus to Acquire Surface Oncology
REDWOOD CITY, Calif. and CAMBRIDGE, Mass., June 16, 2023 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS) and Surface Oncology, Inc. (Surface, Nasdaq: SURF) today announced that the companies have entered into a definitive merger agreement providing that, at the closing, Coherus will acquire Surface Oncology, a clinical-stage immuno-oncology (I-O) company developing next-generation immunotherapies that target the tumor microenvironment. The Surface acquisition adds two differentiated clinical stage assets to Coherus’ novel I-O pipeline: SRF388, a novel IL-27-targeted antibody currently being evaluated in Phase 2 clinical trials in lung cancer and liver cancer, and SFR114, a CCR8-targeted antibody currently in a Phase 1/2 study as a monotherapy in patients with advanced solid tumors.
Elevation Oncology Announces Pricing of $50 Million Public Offering
NEW YORK, June 8, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced the pricing of an underwritten public offering of (i) 17,810,000 shares of its common stock and, in lieu of common stock to investors that so choose, pre-funded warrants to purchase up to an aggregate of 4,440,000 shares of common stock and (ii) accompanying warrants to purchase one share of common stock for each share of common stock or pre-funded warrant sold. The combined offering price to the public of each share of common stock and accompanying warrant is $2.2500. The combined offering price to the public of each pre-funded warrant and accompanying warrant is $2.2499. The accompanying warrants have an exercise price of $2.25 per share, are exercisable immediately, and will expire five years following the date of issuance.
TScan Therapeutics Announces Pricing of $140 Million Public Offering
WALTHAM, Mass., May 26, 2023 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR)-engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced the pricing of an underwritten public offering of 22,989,474 shares of its voting common stock at a public offering price of $2.00 per share, and pre-funded warrants to purchase up to an aggregate of 47,010,526 shares of its common stock at a price to the public of $1.9999 per pre-funded warrant, which represents the per share public offering price for the voting common stock less the $0.0001 per share exercise price for each such pre-funded warrant.
Vedanta Biosciences Announces $106.5 Million Financing to Advance Pipeline of Defined Bacterial Consortia Therapies
CAMBRIDGE, MA, April 25, 2023 – Vedanta Biosciences, a clinical-stage company that is developing a potential new category of oral therapies based on defined bacterial consortia, today announced that it has raised $106.5 million to support pivotal-stage development of its lead candidate, VE303, for the prevention of recurrent Clostridioides difficile infection (CDI), and a Phase 2 study of VE202 for ulcerative colitis, among other development activities. The VE303 study would be the first pivotal Phase 3 study of a therapeutic candidate based on a defined bacterial consortium, which Vedanta is pioneering as a next-generation approach to microbiome therapy. Defined bacterial consortia are products of standardized composition manufactured from cell banks, bypassing the need to rely on donor fecal material of inconsistent composition.
Harpoon Therapeutics Announces Closing of $25 Million Private Placement
SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immuno-oncology company developing novel T cell engagers, today announced that it has closed a private placement of redeemable preferred stock and warrants to purchase common stock to certain institutional and other accredited investors for aggregate gross proceeds to the Company of $25 million, before deducting offering expenses, which does not include any proceeds that may be received upon exercise of the warrants.
ASLAN Pharmaceuticals Announces $20m Private Placement Led by BVF Partners L.P. With The Potential to Receive up to an Additional $80m
San Mateo, California, and Singapore, February 24, 2023 – ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that it has entered into a definitive purchase agreement (“Purchase Agreement”) to raise gross proceeds of approximately $20 million resulting from the sale of its ordinary shares (or pre-funded warrants) and accompanying purchase warrants, at a purchase price of $0.178 per ordinary share (or the equivalent of $0.89 per American Depositary Share (“ADS”)) to BVF Partners L.P., K2 HealthVentures and certain existing investors (the “Investors”). In addition, ASLAN will have the potential to receive up to an additional $80 million if all purchase warrants being issued in connection with the Purchase Agreement are fully exercised.